tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders StocksMarket MoversTipRanks 50 IndexDividend StocksAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
VYNE Therapeutics (VYNE)
NASDAQ:VYNE
US Market
VYNE
VYNE Therapeutics
Overview
Analyst Forecasts
AI Stock Analysis
Popular
Dividends
Earnings
Ownership
Financials
Statistics
New
Technical Analysis
Historical Prices
New
News & Insights
Chart
RESEARCH TOOLS
Top Analyst Stocks
Top Smart Score Stocks
Stock Screener
reports

VYNE Therapeutics (VYNE) Stock News & Sentiment

Compare
1,845 Followers
Promising Potential of VYNE Therapeutics’ Repibresib Gel in Phase IIb Study
Premium
Ratings
Promising Potential of VYNE Therapeutics’ Repibresib Gel in Phase IIb Study
17h ago
VYNE
Promising Outlook for VYNE Therapeutics: Buy Rating Backed by Repibresib’s Potential in Vitiligo Treatment
Premium
Ratings
Promising Outlook for VYNE Therapeutics: Buy Rating Backed by Repibresib’s Potential in Vitiligo Treatment
6d ago
VYNE
VYNE Therapeutics’ VYN202: Regulatory Milestones and Promising Clinical Data Drive Buy Rating
Premium
Ratings
VYNE Therapeutics’ VYN202: Regulatory Milestones and Promising Clinical Data Drive Buy Rating
7d ago
VYNE
Optimistic Outlook for VYNE Therapeutics Amid Promising VYN202 Program Developments
Premium
Ratings
Optimistic Outlook for VYNE Therapeutics Amid Promising VYN202 Program Developments
7d ago
VYNE
VYNE Therapeutics Reports Q1 2025 Financial Results
Premium
Company Announcements
VYNE Therapeutics Reports Q1 2025 Financial Results
2M ago
VYNE
VYNE Therapeutics: Strong Financial Position and Promising Drug Pipeline Justify Buy Rating
Premium
Ratings
VYNE Therapeutics: Strong Financial Position and Promising Drug Pipeline Justify Buy Rating
2M ago
VYNE
Optimistic Buy Rating for VYNE Therapeutics Amid Clinical Challenges and Promising Developments
Premium
Ratings
Optimistic Buy Rating for VYNE Therapeutics Amid Clinical Challenges and Promising Developments
3M ago
VYNE
More VYNE News >

VYNE News on the Web

H.C. Wainwright 'encouraged' by VYNE Therapeutics VYN202 update
The Fly
Neutral
VOR Skyrockets On Ex-China Rights To Autoimmune Drug, ADIL To Face FDA On Jul.29, PSTV Jumps 14%
rttnews
Neutral
VYNE Therapeutics Reports Progress in Clinical Trials
TipRanks News
Neutral
Analysts Offer Insights on Healthcare Companies: VYNE Therapeutics (VYNE), Lexicon Pharmaceuticals (LXRX) and Xtant Medical Holdings (XTNT)
TipRanks News
Neutral
VYNE Therapeutics Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag
Yahoo Finance
Neutral
VYNE Therapeutics Reports 2024 Fourth Quarter and Year-End Financial Results and Provides Business Update
Yahoo Finance
Neutral
VYNE Therapeutics to Participate in March Investor Conferences
Yahoo Finance
Neutral
VYNE Therapeutics Initiates Phase 1b Trial of VYN202, a Novel BD2-Selective Oral BET Inhibitor, in Plaque Psoriasis
Yahoo Finance
Neutral

News Score - Last 7 Days

Neutral
VYNE
Sector Average
Media Buzz
This Week1 articles
Weekly Average1 articles
News Sentiment
This Week50%
Sector Average56%
See how Bullish or Bearish a stock is based on its recent media coverage.

This score is generated using a formula that combines Media Buzz and News Sentiment.

Media Coverage Analysis

The historical news coverage of this asset in the last three months.

FAQ

What is VYNE’s Media Buzz Sentiment?
1 articles about VYNE were published this week. In an average week, 1 articles are published.
    What is VYNE’s weekly average amount of articles?
    In an average week, 1 articles about VYNE are published.
      What is VYNE’s News Sentiment?
      50% of articles about VYNE were positive this week, compared to its sector average of 56%.
        Healthcare Stocks that are Trending in the News
        QDELQuidelOrtho
        MCKMcKesson
        RGTLFArgent Biopharma
        ALHCAlignment Healthcare
        MYGNMyriad Genetics
        Showing the stocks with the most bullish news sentiment over the past week

        Become an Expert with TipRanks Premium

        What am I Missing?
        Make informed decisions based on Top Analysts' activity
        Know what industry insiders are buying
        Get actionable alerts from top Wall Street Analysts
        Find out before anyone else which stock is going to shoot up
        Get powerful stock screeners & detailed portfolio analysis
        Subscribe NowSee Plans & Pricing